Gael Roue

Company: Josep Carreras Leukaemia Research Institute

Job title: Head of the Lymphoma Translational Research Group

Seminars:

Activity of the Novel Bispecific CD47-CD19 Antibody, TG-1801, In Preclinical Models of B-Cell Non-Hodgkin Lymphoma 1:30 pm

TG-1801 is a novel bispecific antibody specifically targeting CD47 in CD19+ cells. TG-1801 facilitates CD20-mediated ADCC and ADCP in in vivo and in vitro models of Burkitt lymphoma by promoting the infiltration of effector cells (NK and macrophages) Phase 1 is ongoing in histologically confirmed B-cell lymphoma relapsed or refractory to prior standard therapyRead more

day: Day Two